Raphael Ognar

Company: NKILT Therapeutics

Job title: President & CEO, Co-Founder - Chairman of the Board

Seminars:

Harnessing Chimeric ILT-Receptor Binding Technology to Target the HLA-G Pathway for Fit-for-Purpose Activation of NK Cells 4:45 pm

Download the event guide for full session detailsRead more

day: Day Two

Panel Discussion: Contrasting Current & Emerging Engineering Strategies to Target Solid Tumors 2:30 pm

Download the event guide for full session detailsRead more

day: Day One Track A PM